Valor202320242025TTMDespesas comerciais, gerais e administrativas6.14 B6.33 B6.09 B6 BPesquisa e desenvolvimento399 M408 M382 M367 MLucro operacional2.51 B1.84 B2.41 B2.62 BLucro não operacional, total-72 M-48 M-36 M-30 MDespesa com juros, líquida de juros capitalizados250 M431 M430 M429 MReceitas não operacionais, líquidas das despesas com juros-308 M-52 M-476 M-469 MReceitas/despesas incomuns-14 M4 M10 M—Lucro antes dos impostos2.19 B1.42 B2 B2.21 BParticipação no lucro————Impostos526 M385 M529 M591 MParticipação de minoritários————Outras receitas/despesas após impostos-6 M-69 M-67 M-69 MLucro líquido antes das operações descontinuadas1.66 B1.03 B1.47 B1.62 BOperações descontinuadas————Lucro líquido1.66 B1.03 B1.47 B1.62 BAjuste de diluição————Dividendos de ações preferenciais————Lucro líquido diluído disponível aos acionistas1.66 B1.03 B1.47 B1.62 BLucro básico por ação0.90.540.770.85Lucro diluído por ação0.90.540.760.84Número médio de ações básicas1.85 B1.92 B1.92 B—Ações diluídas1.85 B1.92 B1.92 B—EBITDA2.35 B1.49 B1.98 B1.82 BEBIT1.2 B860 M1.42 B1.26 BCusto da receita6.8 B6.5 B6.33 B6.37 BOutros componentes do custo————Amortização e depreciação (fluxo de caixa)627 M622 M557 M564 M
Kenvue Inc. Common Stock
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.